Table 1 Characteristics of AML patients who achieved CR1 after intensive chemotherapy

From: Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1

Variable

CC cohort (N = 100)

TCGA cohort (N = 48)

P value

Age

Median, years (range)

58.5 (24–75)

57 (22–77)

0.61

<60 years, %

55

60.4

≥60 years, %

45

40.6

Female, %

48

42

0.39

AML type, %

De novo

76

100

<0.001

Secondary

19

0

Treatment-related

5

0

WBC count ( ×10 9 /L)

Median, range

5.6 (0.55–241)

30.1 (0.6–223.8)

0.001

Bone marrow blasts, %

Median, range

53 (6–95)

75 (34–100)

<0.001

Extramedullary disease, %

Skin

4

NA

 

CNS

2

 

Lymph node

1

 

ELN 2010 classification, %

Intermediate-I

64

81

0.007a

Intermediate-II

36

19

Trisomy 8

7

8.3

MLLT3-MLL present

4

0

Response to first induction b , %

CR

58

NA

 

CRi

11

Persistent disease

31

Number of induction courses to achieve CR1

1

69

NA

 

≥2

31

Time to relapse

Median, range

21 (2–70)

12 (1.7–69)

0.16

Time of HCT, %

In CR1

37

48

0.07

In CR2

13

10

At first relapse

5

0

No HCT

45

42

Type of HCT, %

MSD

41.8

53.4

0.0001

MUD

38.2

30

Haploidentical

18.2

3.3

Auto

0

13.3

UCB

1.8

0

Conditioning regimen

Myeloablative

26

NA

 

BuCy

21

FluTBI

3

Other

2

Reduced-intensity

29

BuFlu

19

FluCyTBI

6

Other

4

  1. AML acute myeloid leukemia, Bu busulfan, CC Cleveland Clinic, CNS central nervous system, CR complete response, CRi CR with incomplete count recovery, Cy cyclophosphamide, Flu fludarabine, HCT hematopoietic cell transplant, MSD matched sibling donor, MUD matched unrelated donor, NA not available, TBI total body irradiation, UCB umbilical cord blood, WBC white blood cell
  2. aP value compares the percentages of patients in intermediate-I risk category
  3. bResponse to first induction was determined by day 14 bone marrow biopsy
Back to article page